Comparative Pharmacology
Head-to-head clinical analysis: NURTEC ODT versus UBRELVY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NURTEC ODT versus UBRELVY.
NURTEC ODT vs UBRELVY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CGRP receptor antagonist; blocks binding of calcitonin gene-related peptide to its receptor, inhibiting vasodilation and neurogenic inflammation in trigeminovascular system.
Calcitonin gene-related peptide (CGRP) receptor antagonist; blocks CGRP-mediated vasodilation and nociception.
75 mg orally once daily as needed, not to exceed 75 mg in 24 hours.
100 mg orally once, may repeat once after at least 2 hours if needed; maximum 200 mg per 24 hours.
None Documented
None Documented
Terminal elimination half-life of approximately 11 hours, supporting twice-daily dosing for migraine prevention.
Terminal elimination half-life is approximately 50 hours, supporting once-daily dosing.
Roughly 75% of dose excreted in feces (as unchanged drug and metabolites), 24% in urine (mostly metabolites, <1% unchanged).
Primarily hepatic metabolism via CYP3A4, with 42% of dose excreted in feces (6% unchanged) and 26% in urine (1% unchanged).
Category C
Category C
CGRP Antagonist
CGRP Antagonist